Sugi Predict

Sugi Predict / Compounds / SCHEMBL15036042

SCHEMBL15036042

SCHEMBL15036042

Cc1nn(S(=O)(=O)c2ccccc2)c(C)c1-c1cc2cnc(Nc3ccc(C4CCCNC4)cc3)nc2n(-c2ccccc2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 11/20 0.39
▸ SRC P12931 2/20 0.39
▸ JAK2 O60674 2/20 0.39
▸ BRD4 O60885 2/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ BRD2 P25440 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ BRD3 Q15059 1/20 0.39
▸ BRDT Q58F21 1/20 0.39
▸ CDK4 P11802 3/20 0.39
▸ CCND1 P24385 3/20 0.39
▸ FGFR1 P11362 2/20 0.39
▸ CCNA2 P20248 2/20 0.39
▸ FGFR2 P21802 2/20 0.39
▸ FGFR4 P22455 2/20 0.39
▸ FGFR3 P22607 2/20 0.39
▸ CDK2 P24941 2/20 0.39
▸ RIPK2 O43353 1/20 0.38
▸ ACVR1 Q04771 1/20 0.38
▸ NOD2 Q9HC29 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13553699 0.80 CDK4 (0.45) WEE1SRCJAK2BRD4JAK1
SCHEMBL15035997 0.78 WEE1 (0.38) WEE1SRCJAK2BRD4CDK4
SCHEMBL15041493 0.77 WEE1 (0.38) WEE1SRCJAK2BRD4CDK4
SCHEMBL15036114 0.77 TNK2 (0.38) WEE1
SCHEMBL15041695 0.76 TNK2 (0.35) —
SCHEMBL15787937 0.75 PKN1 (0.46) WEE1SRCCDK4CCND1FGFR1
SCHEMBL14681986 0.75 USP2 (0.37) WEE1SRCCDK4CCND1FGFR1
SCHEMBL14682014 0.74 JAK2 (0.49) WEE1SRCJAK2BRD4JAK1
SCHEMBL15036115 0.74 JAK2 (0.45) WEE1SRCJAK2BRD4JAK1
SCHEMBL15036123 0.73 CDK4 (0.43) WEE1SRCCDK4CCND1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912203-B2 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders AFRAXIS HOLDINGS, INC. (US) 2014-12-16 — — US disclosed
US-20130252966-A1 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 — — US disclosed
US-20130252966-A1 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 — — US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 — — US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252966-A1 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK6, PAK3 WEE1 1354/4885SRC 222/4885JAK2 288/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 WEE1 545/4885SRC 26/4885JAK2 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.